Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures (2009 - 2018)

Teva Pharmaceutical Industries has disclosed Gains from Sales and Divestitures across 9 years of filings, most recently posting $1.6 million for Q4 2018.

• Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $1.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.6 million (changed N/A YoY) and the FY2018 annual result came in at $1.6 million, changed N/A from the prior year.
• Gains from Sales and Divestitures grew to $1.6 million in Q4 2018, from $830000.0 in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $1.6 million in Q4 2018 and troughed at -$1.1 million in Q4 2015.
• A 4-year average of $625500.0 and a median of $988000.0 in 2014 frame the typical range for Gains from Sales and Divestitures.
• Annual changes were most pronounced in 2015 — Gains from Sales and Divestitures slumped 197.03% — and 2016, when it surged 174.64%.
• Tracing TEVA's Gains from Sales and Divestitures over 4 years: stood at $1.1 million in 2014, then sank by 197.03% to -$1.1 million in 2015, then jumped by 174.64% to $830000.0 in 2016, then soared by 97.35% to $1.6 million in 2018.
• Business Quant data shows TEVA's Gains from Sales and Divestitures at $1.6 million in Q4 2018, $830000.0 in Q4 2016, and -$1.1 million in Q4 2015.